Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma

NCT02976857 is registered in ClinicalTrials.gov with Shanghai AbelZeta Ltd. as lead sponsor.

NCT NCT02976857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02976857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Shanghai AbelZeta Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2016
Completion date
January 9, 2019
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory diffuse large b-cell lymphoma